Previous studies reported that patients with FTDP‐17/MAPT, which could be linked to the same single mutation, demonstrated inter‐ and intrafamilial heterogeneity in clinicopathological features, including ages at onset and death, disease duration, clinical symptoms, brain atrophy, and pathological findings.9, 10, 12, 24 Taken together with the present results, these observations support the view that the MAPT mutation alone may not fully define the clinical and neuropathological outcomes, which could in fact be modulated by other genetic and/or environmental components. Here, MAPT is linked to Brain atrophy.